Kocitaf 50mg/200mg/25mg Tablet is unsafe to utilize in people with liver disease and will be averted.This innovative drug is mainly being explored for its possible part in oncology, notably focusing on different types of cancer. Researchers are investigating its application in autoimmune diseases, aiming to leverage its distinctive system of motion